Genital Warts



A Trial of a New Botanical Drug For the Treatment of External Condylomata Acuminata in Adult Subjects


Condition:   Condylomata Acuminata
Intervention:   Drug: VIR007
Sponsor:   ViroXis Corporation
Not yet recruiting - verified May 2017


Safety and Efficacy of Immune Therapy for Condyloma


Condition:   Condylomata Acuminata
Intervention:   Biological: DC-CIK immunotherapy
Sponsor:   Shenzhen Second People's Hospital
Not yet recruiting - verified March 2017


Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients


Condition:   Genital Wart
Interventions:   Biological: tuberculin;   Device: cryotherapy
Sponsor:   Assiut University
Not yet recruiting - verified May 2017


Assessment of the Predictive Value of the Acetic Acid Test in Surgery Condition for the Detection of Dysplastic Lesions in Patients With Anal Condylomatosis


Condition:   Anal Condyloma
Intervention:   Procedure: acetic acid test
Sponsor:   Hospices Civils de Lyon
Recruiting - verified April 2017


Ano-genital Human Papillomavirus (HPV) Infection, Precancerous Lesions and Genital Warts Among Danish Renal Transplant Recipients


Condition:   Anogenital Dysplasia
Intervention:  
Sponsors:   Bispebjerg Hospital;   Danish Cancer Society
Recruiting - verified January 2017


Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts


Condition:   Condylomata Acuminata (External)
Interventions:   Drug: Omiganan (CLS001) topical gel;   Drug: Vehicle topical gel
Sponsors:   Cutanea Life Sciences, Inc.;   Leiden University Medical Center
Completed - verified March 2017


A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients


Condition:   Condyloma
Interventions:   Drug: AP611074 5% gel;   Drug: AP611074 matching placebo
Sponsor:   Anaconda Pharma
Recruiting - verified May 2017


Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)


Conditions:   Condylomata Acuminata;   Papillomavirus Infections;   Sexually Transmitted Diseases
Interventions:   Drug: Ranpirnase;   Drug: Vehicle
Sponsor:   Tamir Biotechnology, Inc.
Completed - verified March 2017


Carbon Dioxide Laser vs. Electrocoagulation for the Therapy of Condyloma


Condition:   Condylomata Acuminata
Interventions:   Device: Carbon dioxide Laser ablation;   Device: Electrocoagulation
Sponsors:   Zydolab - Institute of Cytology and Immune Cytochemistry;   Ruhr University of Bochum
Recruiting - verified October 2016


Topical NVN1000 for the Treatment of External Genital and Perianal Warts


Conditions:   Genital Warts;   Perianal Warts
Interventions:   Drug: NVN1000;   Other: Vehicle Gel
Sponsors:   Novan, Inc.;   PPD
Active, not recruiting - verified January 2017


Efficacy and Tolerability of Topical LFX453 for External Genital Warts


Condition:   External Genital Warts
Interventions:   Drug: LFX453;   Drug: Aldara®
Sponsor:   Novartis Pharmaceuticals
Completed - verified May 2017


Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine


Condition:   Condylomata Acuminata
Interventions:   Biological: low dosage HPV Vaccine;   Biological: medium dosage HPV Vaccine;   Biological: high dosage HPV Vaccine;   Biological: Aluminium Adjuvant
Sponsors:   Jun Zhang;   Xiamen Innovax Biotech Co., Ltd;   Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Active, not recruiting - verified December 2015


Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts


Condition:   Anogenital Warts
Intervention:   Drug: Picato
Sponsor:   LEO Pharma
Completed - verified May 2017


The Epidemiologic Study of Human Papillomavirus Infection and Related Diseases


Conditions:   Human Papillomavirus Infection;   Genital Warts
Intervention:  
Sponsors:   Jun Zhang;   Liuzhou center of disease prevention and control
Completed - verified July 2014


Safety and Efficacy Double Blind Vehicle Controlled Study of 15% AS101 Gel to Treat External Genital Warts


Condition:   External Genital Warts
Interventions:   Drug: 15% AS101 gel;   Drug: Vehicle
Sponsor:   BioMAS Ltd
Recruiting - verified October 2016


Safety Study of Multikine in the Treatment of Perianal Warts


Condition:   Condyloma
Interventions:   Drug: Leukocyte Interleukin, Injection 200IU;   Drug: Leukocyte Interleukin, injection 400IU
Sponsors:   United States Naval Medical Center, San Diego;   CEL-SCI Corporation
Terminated - verified August 2016


A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts


Conditions:   Anogenital Warts;   Condylomata Acuminata
Interventions:   Drug: Topical NO;   Drug: Placebo
Sponsors:   University of Aberdeen;   Prostrakan Pharmaceuticals;   Erasmus Medical Center
Completed - verified December 2013


Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)


Conditions:   Genital Warts;   Anal Cancer;   Anal Intraepithelial Neoplasia
Intervention:   Biological: 9vHPV Vaccine
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017


A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts


Conditions:   Genital Warts;   HPV
Interventions:   Drug: Oral Zinc;   Drug: Placebo
Sponsors:   University of British Columbia;   British Columbia Centre for Disease Control
Terminated - verified October 2016


A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)


Conditions:   Cervical Cancers;   Vulvar Cancers;   Vaginal Cancers;   Genital Warts
Interventions:   Biological: V503;   Biological: Placebo to V503
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017


The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata


Conditions:   HIV Positive;   Anal Condylomata;   Anal Warts;   HIV Infections
Interventions:   Drug: Saline;   Drug: Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
Sponsor:   Washington University School of Medicine
Completed - verified June 2016


Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)


Conditions:   Cervical Cancer;   Genital Warts
Interventions:   Biological: V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years;   Biological: Comparator: placebo (concomitant-vaccine matched) / Duration of Treatment : 4 Years
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017


Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015)


Conditions:   Cervical Cancer;   Genital Warts
Interventions:   Biological: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine;   Biological: Matching Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified January 2017


Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)


Conditions:   Cervical Cancer;   Genital Warts
Intervention:   Biological: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017


An Investigational Study of Gardasil™ (qHPV, V501) Vaccine in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)


Condition:   Condylomata Acuminata
Interventions:   Biological: (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine;   Biological: Comparator: placebo (unspecified)
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified April 2017

Refine Your Search Advanced Search